While physiologically involved in barrier integrity and immune defense, aberrant Gal-4 expression in gastric cancer has been linked to enhanced proliferation, receptor activation, and peritoneal dissemination, underscoring its emerging relevance as a biomarker and potential therapeutic target. This evidence concerns the gene LGALS4 and gastric cancer.